BCM
ARQT icon

Bayesian Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Bayesian Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,000
Closed -$452K – 145
2025
Q3 		$452K Buy
24,000
+10,100
+73% +$159K 0.09% 296
2025
Q2 		$195K Buy
+13,900
New +$195K 0.03% 463
2025
Q1 		– Sell
-17,587
Closed -$245K – 599
2024
Q4 		$245K Buy
+17,587
New +$193K 0.03% 531

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bayesian Capital Management's ARQT Position: Q4 2025 in Review

Bayesian Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 24,000 shares — an estimated $452K sold.

Bayesian Capital Management first reported a position in ARQT in Q4 2024 and held it in 3 quarters. The position peaked at $452K in Q3 2025. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Bayesian Capital Management reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 24,000 Arcutis Biotherapeutics shares in Q4 2025, an estimated $452K.
  • Bayesian Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 3 quarters.
  • Bayesian Capital Management's Arcutis Biotherapeutics position peaked at $452K in Q3 2025.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.